Rhythm Pharmaceuticals received a three‑month extension from the U.S. Food and Drug Administration to review its supplemental New Drug Application for setmelanotide in acquired hypothalamic obesity, moving the PDUFA goal date from December 20 2025 to March 20 2026.
Continue reading for full analysis...